eFFECTOR Therapeutics, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 36.58. In total, the insiders bought 6 117 509 and sold 974 418 EFTR shares in the last 100 trades.

Insider Power

(Last 100 transactions)
36.58
Buy 6 117 509 Shares
Sell 974 418 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 13, 2024 Stock Option (Right to Buy) Buy Loewy Caroline M 800
Jun 13, 2024 Stock Option (Right to Buy) Buy Klencke Barbara 800
Jun 13, 2024 Stock Option (Right to Buy) Buy Ehrlich Christopher B 800
Jun 13, 2024 Stock Option (Right to Buy) Buy Harrington-smith Kristen 800
Jun 13, 2024 Stock Option (Right to Buy) Buy Gallagher Brian M. Jr. 800
Jun 13, 2024 Stock Option (Right to Buy) Buy Bhatt Elizabeth 800
May 15, 2024 Common Stock Buy Byrnes Michael 1 387
May 15, 2024 Common Stock Buy Worland Stephen T 1 806
Feb 19, 2024 Stock Option (Right to Buy) Buy Loewy Caroline M 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Bhatt Elizabeth 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Ehrlich Christopher B 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Klencke Barbara 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Harrington-smith Kristen 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Gallagher Brian M. Jr. 2 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Byrnes Michael 40 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Warner Douglas J 25 000
Feb 19, 2024 Stock Option (Right to Buy) Buy Worland Stephen T 80 000
Nov 27, 2023 Common Stock Sell Sr One Capital Management, Llc 430 578
Nov 27, 2023 Common Stock Sell Sr One Capital Management, Llc 178 585
Nov 15, 2023 Common Stock Buy Worland Stephen T 5 979
Nov 15, 2023 Common Stock Buy Byrnes Michael 4 524
Sep 09, 2023 Stock Option (Right to Buy) Buy Loewy Caroline M 40 000
Sep 09, 2023 Common Stock Buy Loewy Caroline M 0
Aug 11, 2023 Common Stock Buy Worland Stephen T 33 799
Aug 11, 2023 Stock Option (Right to Buy) Sell Worland Stephen T 33 799
Click to get the best stock tips daily for free!

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk... EFTR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT